Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Policy
GSK Report Details Aid To Poor Nations
by Rick Mullin
March 30, 2009
| A version of this story appeared in
Volume 87, Issue 13
GlaxoSmithKline's 2008 corporate responsibility report, published last week, states that the firm will contribute 500 granted and 300 pending patents to an intellectual property pool for research on treating neglected tropical diseases. The patent pool was proposed by CEO Andrew Witty at Harvard University last month (C&EN, Feb. 23, page 8). GSK also restated Witty's commitment to reducing the cost of drugs for the least developed countries to 25% of their cost in developed countries, as long as the firm can recoup the cost of goods.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter